Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Kramer

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|March 13, 2024
Profiling Cell Heterogeneity and Fructose Transporter Expression in the Rat Nephron by Integrating Single-Cell and Microdissected Tubule Segment TranscriptomesRonghao Zhang, Darshan Aatmaram Jadhav, Najeong Kim, et al.
Clinical Therapeutics|December 20, 2011
Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesEdward M Kerwin, Mark H Gotfried, David Lawrence, et al.
Respiratory Medicine|March 15, 2011
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPDPaul W Jones, Donald A Mahler, Rupert Gale, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 22, 2010
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneBeatrix Balint, Henrik Watz, Carolynn Amos, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 18, 2011
Safety of indacaterol in the treatment of patients with COPDJames F Donohue, Dave Singh, Oliver Kornmann, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Allergy and Asthma Proceedings|April 2, 2004
Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitisJames H Day, Maureen P Briscoe, Elizabeth Rafeiro, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 17, 2022
Aortic diameter is a poor predictor of aortic tissue failure metrics in patients with ascending aneurysmsEmily Vianna, Benjamin Kramer, Samar Tarraf, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|March 13, 2024
Profiling Cell Heterogeneity and Fructose Transporter Expression in the Rat Nephron by Integrating Single-Cell and Microdissected Tubule Segment TranscriptomesRonghao Zhang, Darshan Aatmaram Jadhav, Najeong Kim, et al.
Clinical Therapeutics|December 20, 2011
Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesEdward M Kerwin, Mark H Gotfried, David Lawrence, et al.
Respiratory Medicine|March 15, 2011
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPDPaul W Jones, Donald A Mahler, Rupert Gale, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 22, 2010
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneBeatrix Balint, Henrik Watz, Carolynn Amos, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 18, 2011
Safety of indacaterol in the treatment of patients with COPDJames F Donohue, Dave Singh, Oliver Kornmann, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Allergy and Asthma Proceedings|April 2, 2004
Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitisJames H Day, Maureen P Briscoe, Elizabeth Rafeiro, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 17, 2022
Aortic diameter is a poor predictor of aortic tissue failure metrics in patients with ascending aneurysmsEmily Vianna, Benjamin Kramer, Samar Tarraf, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
Pageof 6